Tryten Announces the Virtual Rounding Assistant-Tablet Cart to Support the Expansion of Efforts to Stop COVID-19

Tryten notes COVID-19 is hitting record high infections, hospitalizations, and ICU bed occupancy reports

The company recently surpassed 500,000 deaths due to the virus. Hospitals and community health centers need solutions to rapidly meet the increasing demand for remote providers to safely access their patients. Healthcare delivery is moving into stadiums, temporary tents, and reconfigured hospital facilities.

Providers need access to many different locations to support vaccinations, testing, and delivery of care. Tablet-based virtual rounding can quickly bring remote experts to the point of care to safely leverage expertise across different locations. Curbside virtual care can move to stadiums, and temporary locations to expedite the delivery of vaccines and patient care.

Tryten’s Virtual Rounding Assistant-Tablet Cart is lightweight, easy to position and install. It supports BYO tablet and video. It is easily incorporated into current IT architectures. The elegant design includes cable management, an easy-to-position articulating arm, and various secure tablet mounts to enable rotation and tilt of the tablet. Tryten partners are available to provide the total solution including tablet, video, and services.

“Many have turned to virtual care to provide safe ways to leverage their resources. Virtual rounding has surfaced as an important tool to bring care to patients safely and to workload balance across providers. Tryten’s Virtual Rounding Assistant -Tablet Cart enables healthcare organizations to quickly mobilize their tablets and video telehealth tools. It can be deployed to support vaccination, triage, and testing. Nurses can use it as they collect vitals or doctors can use it for telehealth and rounding. We are determined to do our part to fight the virus and help those on the frontlines,” said Dr. Deborah Jeffries, Global Director of Healthcare for Tryten.

Tony Janzen, CEO and Founder of the company states, “Tryten is making every effort to bring effective, easy-to-deploy solutions to the market that can support our efforts to defeat COVID-19. Our entire team is focused on ways we can make a difference.”

 

SourceTryten

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version